



Press Release

Immudex Collaborates with BD to Create Improved Solutions for T cell Multiomic Research

Immudex Aps, a privately held life science company, today announced a collaboration agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, to develop dCODE Dextramer® reagents compatible with the BD Rhapsody™ single cell analysis system, a platform for single cell multiomic analysis with the ability to detect molecules responsible for biological diversity.

The dCODE Dextramer® technology is the most sensitive method to directly detect disease-specific T cells based on TCR recognition and DNA barcode labels. Incorporation of dCODE Dextramer® technology into the BD single cell multiomic analysis ecosystem creates a powerful new workflow for discovery of T cell correlation and investigation of the antigen-specific T cell response.

"Understanding the antigen-specific T cell response is critical for the development of improved immunotherapies for cancer, autoimmune disease and vaccines, which are particularly relevant as the world looks to better understand COVID-19 and develop vaccines," said Stephen T. Haley, PhD, Global Strategic Alliances at Immudex.

"Global gene expression studies have failed to elucidate the role of antigen-specific T cells because of their rarity. The increased resolution and customer friendly workflow enabled by the combined technologies will open doors to easier and more targeted discovery of disease-specific T cell responses," said Liselotte Brix, Chief Scientific Officer of Immudex.

The BD Rhapsody™ system overcomes the limitations of traditional assays, such as microarrays and bulk RNAseq, which rely upon averaging measurements across multiple cells. With the novel single cell separation technology users can observe highly subtle differences between individual cells and identify and characterize novel and rare cell types helping further the understanding of biological processes in fields ranging from immunology to oncology and beyond. The BD Rhapsody™ system profiles the gene, protein and TCR expression of thousands of single cells, with predesigned or customized assays flexible enough to meet many experimental need and QC every step of the workflow.

Information on dCODE Dextramer® technology is available at www.immudex.com. More information on the BD Rhapsody™ system and the new BD single cell multiplexing assay is available at <https://www.bdbiosciences.com/en-us/instruments/research-instruments/single-cell-multiomics/single-cell-analysis-system>. The dCODE Dextramer® technology and BD Rhapsody™ system are for research use only and not for diagnostic or therapeutic use.

About Immudex

Based in Copenhagen, Denmark with North American operations based in Fairfax, Virginia, Immudex is the sole proprietor of DNA barcoded MHC multimer technology. The dCODE Dextramer® technology is an advanced development of Immudex proprietary MHC Dextramer reagents, which are superior for the detection of antigen-specific T cells. The dCODE® technology enables massive multiplexing of antigen-specific T-cell detection overcoming the limitations of earlier technologies.